Chelsi Stearns, NP
Family · Columbus, INNPI 1306495890
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,163 of the $3,271 with a category attached, or 66.1%. Organon accounts for 67.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2023 at $2,583 and has fallen 89.3% since, to $275 in 2025.
Across 65 payments — averaging $50.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$2K
- AbbVie$193
- Astellas Pharma US Inc$134
- Axonics, Inc.$114
- Exeltis, USA Inc.$95
- Pfizer$87
- plus $442 from 12 others
What the payments were for
- Speaking & faculty fees$2,16366%
- Food & beverage$1,10734%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 8 | $2,206 |
| AbbVie | 11 | $193 |
| Astellas Pharma US Inc | 7 | $134 |
| Axonics, Inc. | 4 | $114 |
| Exeltis, USA Inc. | 7 | $95 |
| Pfizer | 6 | $87 |
| Hologic Sales And Service, LLC | 3 | $71 |
| Biogen | 3 | $68 |
| Mayne Pharma Commercial LLC | 2 | $47 |
| Myovant Sciences Inc. | 2 | $47 |
| Coopersurgical, Inc. | 2 | $40 |
| Exact Sciences | 2 | $38 |
| Bayer | 2 | $34 |
| Therapeuticsmd, Inc. | 2 | $27 |
| Agile Therapeutics, Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $17 |
| Millicent US Inc | 1 | $16 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEXPLANON$2,090
How this compares
$3,271 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 21 | $1,070 |
| YuvafemEstradiol | 13 | $878 |
| Clobetasol Propionate | 12 | $290 |
| Gabapentin | 12 | $55 |
Paid to pharmacies, not to this prescriber.
Other family in Columbus
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.